APCN 2021: New paradigm in CKD treatment with SGLT2 inhibitors
Chronic kidney disease (CKD) is a serious and progressive condition, which presents a considerable health burden throughout the world. Early screening and treatment may help improve renal outcomes and reduce the associated risk of mortality. At the Asian Pacific Congress of Nephrology (APCN) 2021, Professor Sydney Tang of the University of Hong Kong and Professor David Wheeler of the University College London, UK, discussed the importance of CKD screening and reviewed treatment options. 

New Molecule

1 New

New Indication

7 New

New Presentation

1 New

New Brand

11 New

Markings
Shape
Form
Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in